One of the main challenges in targeting MDM2 is achieving selectivity without affecting other proteins involved in the ubiquitin-proteasome system. Off-target effects can lead to unintended consequences, impacting cellular processes beyond p53 regulation. Additionally, the development of resistance to MDM2 inhibitors is a concern, necessitating combination therapies to enhance treatment efficacy.
